Zimmer Biomet (ZBH) Stock Price, News & Analysis

Company Overview

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications. Zimmer Biomet sells its products to hospitals, ambulatory surgery centers and healthcare professionals.

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet serves healthcare markets worldwide through direct operations and independent distributors. The company has expanded its offerings through internal development and acquisitions, including the acquisition of Biomet in 2015, which created the current Zimmer Biomet organization. Ivan Tornos serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $90.60 to $91.59
• 50-Day Range: $88.79 to $101.41
• 52-Week Range: $79.12 to $106.88
• Volume: 1.46 million shs
• Average Volume: 1.99 million shs
• Market Capitalization: $17.41 billion
• P/E Ratio: 22.21
• Dividend Yield: 1.05%
• Price Target: $103.00
• Consensus Rating: Hold

Zimmer Biomet Stock Analysis - MarketRank™

Zimmer Biomet scored higher than 77% of companies evaluated by MarketBeat, and ranked 136th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 6 buy ratings, 14 hold ratings, and 2 sell ratings.

Upside Potential

Zimmer Biomet has a consensus price target of $103.00, representing about 12.8% upside from its current price of $91.27.

Amount of Analyst Coverage

Zimmer Biomet has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.27%

Earnings Growth

Earnings for Zimmer Biomet are expected to grow by 5.27% in the coming year, from $8.54 to $8.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zimmer Biomet is 22.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zimmer Biomet is 22.21, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.78.

Price to Earnings Growth Ratio

Zimmer Biomet has a PEG Ratio of 1.73. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zimmer Biomet has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.55% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 2.41%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Zimmer Biomet pays a meaningful dividend of 1.05%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zimmer Biomet does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Zimmer Biomet is 23.36%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.68% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.82

News Sentiment

Zimmer Biomet has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Zimmer Biomet this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for ZBH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $824,028.00 in company stock.

Percentage Held by Insiders

1.28% of the stock of Zimmer Biomet is held by insiders.

Percentage Held by Institutions

88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 7/31 Dividend: 6/25/2026
• Ex-Dividend for 7/31 Dividend: 6/25/2026
• Dividend Payable: 7/31/2026
• Last Earnings: 8/05/2026
• Today: 9/29/2026
• Record date for 10/30 Dividend: 9/30/2026
• Ex-Dividend for 10/30 Dividend: 9/30/2026
• Dividend Payable: 10/30/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:ZBH
• Previous Symbol: NYSE:ZMH
• CIK: 1136869
• Web: www.zimmerbiomet.com
• Phone: (574) 267-6131
• Fax: 574-372-4988
• Employees: 17,000
• Year Founded: 1927

Price Target and Rating

• Average Price Target for Zimmer Biomet: $103.00
• High Price Target: $120.00
• Low Price Target: $90.00
• Potential Upside/Downside: +12.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.11
• Trailing P/E Ratio: 22.21
• Forward P/E Ratio: 10.69
• P/E Growth: 1.73
• Net Income: $705.20 million
• Net Margins: 9.48%
• Pretax Margin: 10.97%
• Return on Equity: 13.12%
• Return on Assets: 7.23%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.69
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: $8.23 billion
• Price / Sales: 2.11
• Cash Flow: $13.68 per share
• Price / Cash Flow: 6.67
• Book Value: $64.11 per share
• Price / Book: 1.42

Miscellaneous

• Outstanding Shares: 190,740,000
• Free Float: 188,297,000
• Market Cap: $17.41 billion
• Optionable: Optionable
• Beta: 0.47